跳转至内容
Merck
CN

F6800

Fenoldopam monohydrobromide

≥98%

别名:

6-Chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzazepine-7,8-diol monohydrobromide, SKF-82526

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C16H16ClNO3 · HBr
化学文摘社编号:
分子量:
386.67
UNSPSC Code:
12352200
PubChem Substance ID:
EC Number:
266-634-7
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI key

DSGOSRLTVBPLCU-UHFFFAOYSA-N

InChI

1S/C16H16ClNO3.BrH/c17-15-11-5-6-18-8-13(9-1-3-10(19)4-2-9)12(11)7-14(20)16(15)21;/h1-4,7,13,18-21H,5-6,8H2;1H

SMILES string

ClC1=C(O)C(O)=CC2=C1CCNCC2C3=CC=C(O)C=C3.[H]Br

assay

≥98%

form

solid

storage condition

protect from light, under inert gas

color

off-white

solubility

DMSO: >12 mg/mL, H2O: 4.75 mg/mL

storage temp.

2-8°C

Gene Information

Biochem/physiol Actions

Fenoldopam is a selective dopamine agonist that is being considered for the parenteral treatment of systemic hypertension. In both an oral and parenteral form, fenoldopam causes peripheral vasodilation by stimulating dopamine-1 adrenergic receptors. Intravenous fenoldopam may provide advantages over sodium nitroprusside because it can induce both a diuresis and natriuresis, is not light sensitive, and is not associated with cyanide toxicity. There is no evidence for rebound hypertension after discontinuation of fenoldopam infusion.

Features and Benefits

This compound was developed by Hospira. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Health hazardExclamation mark

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Resp. Sens. 1 - Skin Sens. 1

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

T Hussain et al.
The American journal of physiology, 272(3 Pt 2), F339-F346 (1997-03-01)
The dopamine DA1 receptor transduces its signal via adenylyl cyclase and phospholipase C in the renal proximal tubule, which has been suggested to be defective at the level of receptor-G protein coupling in spontaneously hypertensive rats (SHR). We prepared basolateral
P A de Vries et al.
Journal of cardiovascular pharmacology, 34(2), 191-198 (1999-08-13)
The natriuretic response to a dopamine 1-like receptor agonist is blunted in spontaneously hypertensive rats (SHRs). Whether the renal vasodilator response to D1-like receptor stimulation in SHRs is defective also is unclear. To determine whether the renal hemodynamic response to
M Quevedo et al.
General pharmacology, 32(1), 123-125 (1999-01-15)
1. Fenoldopam mesylate, a benzazepine derivative, is a D1 receptor agonist that lowers blood pressure through vasodilation of renal, mesenteric, coronary and cerebral vascular beds. 2. Experiments were performed in rats, and mean carotid blood pressure and heart rate were
R A Hahn et al.
The Journal of pharmacology and experimental therapeutics, 223(2), 305-313 (1982-11-01)
SK&F 82526 (6-chloro-7,8-dihydroxy-1-(p-hydroxyphenyl)-2,3,4,5-tetrahydro-(1H)-3-benzazepine) was evaluated for its peripheral cardiovascular activity, effect on renal and central dopamine receptors and mechanism of action. Comparisons were made with dopamine. In anesthetized dogs, SK&F 82526 i.v., produced dose-related dilation of the renal vasculature, apparently
U Venkatakrishnan et al.
Clinical and experimental hypertension (New York, N.Y. : 1993), 22(3), 309-324 (2000-05-10)
Dopamine and dopamine-1 receptor agonists produce diuresis and natriuresis by causing changes in renal hemodynamics and by the activation of dopamine-1 receptors located within the various regions of the nephron. Nitric oxide plays an important role in the maintenance of

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持